Director’s appointment – additional information under Listing Rule 9.6.13(1)
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
("Mediclinic", or the "Company", or the "Group")
3 August 2021
DIRECTOR’S APPOINTMENT – ADDITIONAL INFORMATION UNDER LISTING RULE 9.6.13(1)
Further to the announcement made by Mediclinic on 27 July 2021 regarding the appointment of two
new independent non-executive directors (RNS Number: 6305G), this notification sets out certain
additional details regarding Zarina Bassa’s external appointments, in accordance with LR 9.6.13 R(1)
of the United Kingdom’s Financial Conduct Authority’s Listing Rules.
As part of her appointment as the senior independent director of Investec plc and Investec Ltd (the
specialist banking and wealth management group with a dual listed company structure and listings on
the London Stock Exchange [the "LSE"] and the JSE), Zarina is also a director of three subsidiaries of
those companies: Investec Bank plc, Investec Bank Ltd and Investec Bank (Mauritius) Limited, which
have securities listed on the LSE or the JSE. Her past appointments include being a non-executive
director of Senwes Limited.
There are no further disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R in respect of
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
At 30 June 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case
clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The Company’s primary listing is on the LSE in the United Kingdom, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 03-08-2021 05:48:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.